Search Results - "TEICHER, B. A"

Refine Results
  1. 1

    The Proteasome Inhibitor PS-341 in Cancer Therapy by TEICHER, B. A, ARA, G, HERBST, R, PALOMBELLA, V. J, ADAMS, J

    Published in Clinical cancer research (01-09-1999)
    “…The anticancer activity of the boronic acid dipeptide proteasome inhibitor PS-341 was examined in vitro and in vivo . PS-341 was a potent cytotoxic agent…”
    Get full text
    Journal Article
  2. 2

    Antibody-drug conjugate targets by Teicher, B A

    Published in Current cancer drug targets (01-12-2009)
    “…The requirements for a cell surface molecule to be suitable as an antibody-drug conjugate target are stringent. The notion that antibodies-directed toward…”
    Get more information
    Journal Article
  3. 3

    Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides by Shih, C, Teicher, B A

    Published in Current pharmaceutical design (01-09-2001)
    “…The antitumor cryptophycins are synthetic derivatives of the desipeptide cryptophycins isolated from the cyanobacterium Nostoc sp. Cryptophycin 52 that is…”
    Get more information
    Journal Article
  4. 4

    A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy by Antman, K, Ayash, L, Elias, A, Wheeler, C, Hunt, M, Eder, J P, Teicher, B A, Critchlow, J, Bibbo, J, Schnipper, L E

    Published in Journal of clinical oncology (01-01-1992)
    “…The study was designed to determine the duration of complete response (CR) for patients with unresectable or metastatic breast cancer treated with high-dose…”
    Get more information
    Journal Article
  5. 5

    Acquired Multicellular-Mediated Resistance to Alkylating Agents in Cancer by Kobayashi, Hiroaki, Man, Shan, Graham, Charles H., Kapitain, Sean J., Teicher, Beverly A., Kerbel, Robert S.

    “…EMT-6 murine mammary tumor sublines highly resistant to cyclophosphamide, cis-diamminedichloroplatinum(II), or N,N',N''-triethylenethiophosphoramide were…”
    Get full text
    Journal Article
  6. 6

    Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease by TEICHER, B. A, ALVAREZ SOTOMAYOR, E, ZHEN DONG HUANG

    Published in Cancer research (Chicago, Ill.) (01-12-1992)
    “…The formation of a blood supply (angiogenesis) is critical to the growth of solid tumors. The naturally occurring steroid tetrahydrocortisol, the synthetic…”
    Get full text
    Journal Article
  7. 7

    Effects of the flavonoid drug quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo by Asea, A, Ara, G, Teicher, B A, Stevenson, M A, Calderwood, S K

    Published in International journal of hyperthermia (01-07-2001)
    “…Tumour hyperthermia, although potentially a powerful therapeutic agent and radiation sensitizer, is hindered by a number of considerations including…”
    Get more information
    Journal Article
  8. 8
  9. 9

    Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents by KAKEJI, Y, TEICHER, B. A

    Published in Investigational new drugs (01-01-1997)
    “…TNP-740, minocycline, suramin and genistein have demonstrated antiangiogenic activity in various experimental systems. The effect of these agents alone and in…”
    Get full text
    Journal Article
  10. 10
  11. 11

    Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents by Teicher, B A, Holden, S A, Ara, G, Sotomayor, E A, Huang, Z D, Chen, Y N, Brem, H

    Published in International journal of cancer (15-06-1994)
    “…The ability of TNP-470, a synthetic analog of fumagillin which has been described as an anti-angiogenic agent, to potentiate cytotoxic cancer therapies was…”
    Get more information
    Journal Article
  12. 12

    Transforming growth factor-beta and response to anticancer therapies in human liver and gastric tumors in vitro and in vivo by Liu, P, Menon, K, Alvarez, E, Lu, K, Teicher, B A

    Published in International journal of oncology (01-03-2000)
    “…Liver cancer and gastric cancer are the most common solid tumors worldwide. Transforming growth factor-beta (TGF-beta) production and lack of response to…”
    Get more information
    Journal Article
  13. 13

    Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma by TEICHER, B. A, HOLDEN, S. A, ARA, G, KORBUT, T, MENON, K

    “…The efficacy of several potential antiangiogenic agents, TNP-470, minocycline, suramin, genistein, interferon delta 4, 14(sulfated)-beta-cyclodextrin and…”
    Get full text
    Journal Article
  14. 14

    A carbonic anhydrase inhibitor as a potential modulator of cancer therapies by Teicher, B A, Liu, S D, Liu, J T, Holden, S A, Herman, T S

    Published in Anticancer research (01-09-1993)
    “…Since several anticancer drugs are known to become more cytotoxic to cells in an acidic milieu, we have attempted to utilize the carbonic anhydrase inhibitor,…”
    Get more information
    Journal Article
  15. 15

    Oxymetry Deep in Tissues With Low-Frequency Electron Paramagnetic Resonance by Halpern, Howard J., Yu, Cheng, Peric, Miroslav, Barth, Eugene, Grdina, David J., Teicher, Beverly A.

    “…We have measured the oxygen concentration in the body water of murine FSa and NFSa fibrosarcomas using a new method for quantitative oxygen concentration…”
    Get full text
    Journal Article
  16. 16

    Antitumor activity of cryptophycins: effect of infusion time and combination studies by MENON, K, ALVAREZ, E, FORLER, P, PHARES, V, AMSRUD, T, SHIH, C, AL-AWAR, R, TEICHER, B. A

    “…Cryptophycins are a family of antitubulin antitumor agents. A synthetic cryptophycin derivative (LY355703, CRYPTO 52) is in early clinical evaluation. The…”
    Get full text
    Journal Article
  17. 17

    Overexpression of Metallothionein Confers Resistance to Anticancer Drugs by Kelley, Susan L., Basu, Alakananda, Teicher, Beverly A., Hacker, Miles P., Hamer, Dean H., Lazo, John S.

    “…Resistance to antineoplastic agents is the major obstacle to curative therapy of cancer. Tumor cell lines with acquired resistance to the antineoplastic agent…”
    Get full text
    Journal Article
  18. 18

    Diminished aqueous microviscosity of tumors in murine models measured with in vivo radiofrequency electron paramagnetic resonance by HALPERN, H. J, CHANDRAMOULI, G. V. R, BARTH, E. D, CHENG YU, PERIC, M, GRDINA, D. J, TEICHER, B. A

    Published in Cancer research (Chicago, Ill.) (15-11-1999)
    “…Using very low frequency in vivo electron paramagnetic resonance (EPR), we have compared, for the first time, the average microviscosity of the total aqueous…”
    Get full text
    Journal Article
  19. 19

    Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma by TEICHER, B. A, ARA, G, BUXTON, D, LEONARD, J, SCHAUB, R. G

    Published in Clinical cancer research (01-09-1997)
    “…The antitumor activity of interleukin (IL)-12, a naturally occurring cytokine, has been demonstrated in several murine solid tumors. Animals bearing…”
    Get full text
    Journal Article
  20. 20

    Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy by Teicher, B A, Holden, S A, Ara, G, Dupuis, N P, Liu, F, Yuan, J, Ikebe, M, Kakeji, Y

    Published in International journal of cancer (29-05-1995)
    “…Tissue oxygen tensions were measured in subcutaneously growing rat 9L gliosarcoma under normal air and carbogen breathing conditions prior to and after i.v…”
    Get more information
    Journal Article